AVAvinashnarayan Venkatanarayan

Avinashnarayan Venkatanarayan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Avinashnarayan Venkatanarayan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

    by Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, et al.

    Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with cetuximab- but not bevacizumab-containing therapies; thus, this suggests that ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.


  • Dimerization Induced by C-Terminal 14–3–3 Binding Is Sufficient for BRAF Kinase Activation

    by Nicholas P. D. Liau, Avinashnarayan Venkatanarayan, John G. Quinn, Wilson Phung, Shiva Malek, Sarah G. Hymowitz, Jawahar Sudhamsu

    The Ras-RAF-MEK-ERK signaling axis, commonly mutated in human cancers, is highly regulated to prevent aberrant signaling in healthy cells. One of the pathway modulators, 14-3-3, a constitutive dimer, induces RAF dimerization and activation by binding to a phosphorylated motif C-terminal to the RAF kinase domain. Recent work has suggested that a C-terminal “DTS” region in BRAF is necessary for this 14-3-3 mediated activation. We show that the catalytic activity and ATP binding affinity of the BRAF:14-3-3 complex is insensitive to the presence or absence of the DTS, whilst the ATP sites of both BRAF molecules are identical and available for binding. We also present a crystal structure of the apo BRAF:14-3-3 complex showing that the DTS is not required to attain the catalytically active conformation of BRAF. Rather, BRAF dimerization induced by 14-3-3 is the key step in activation, allowing the active BRAF:14-3-3 tetramer to achieve catalytic activity comparable to the constitutively active oncogenic BRAF V600E mutant.